Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Omega Therapeutics (OMGA – Research Report) today and set a price target of $9.00. The company’s shares closed yesterday at $3.01.
According to TipRanks, Tenthoff is a 4-star analyst with an average return of 3.5% and a 37.95% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Moderna, and Arrowhead Pharmaceuticals.
Omega Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $11.00.
The company has a one-year high of $10.09 and a one-year low of $1.30. Currently, Omega Therapeutics has an average volume of 2.23M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omega Therapeutics (OMGA) Company Description:
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human medicine through highly selective and direct control of the human genome to treat and cure disease.
Read More on OMGA:
- Omega Therapeutics price target lowered to $7 from $12 at Chardan
- Omega Therapeutics sees cash runway into 1Q25
- Omega Therapeutics announces strategic prioritization, reduces headcount by 35%
- Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
- Omega Therapeutics reports Q4 EPS (37c), consensus (45c)
